ArticleMolecular cell2020
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.
Article in Molecular cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection.PLoS pathogens · 2022Trial
- Inhibitory effects of molnupiravir on Crimean-Congo hemorrhagic fever virus polymerase.NAR molecular medicine · 2026Article
- Late-stage adenine N6-alkylation of nucleos(t)ides and oligonucleotides via photoredox and copper co-catalytic decarboxylative C(sp3)-N coupling.Nature communications · 2025Article
- Review
- Analysis of SARS-CoV-2 genome evolutionary patterns.Microbiology spectrum · 2024Article
- Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir.Npj viruses · 2024Article
- Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence.Infectious disease reports · 2023Review
- MAb Targeting a Link Between ExoN and MTase of TGEV NSP14.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2023Article
- Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.Journal of infection and public health · 2023Article
- Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice.NPJ vaccines · 2023Article
- Viral Nucleases.Viruses · 2023Article
- Cellular APOBEC3A deaminase drives mutations in the SARS-CoV-2 genome.Nucleic acids research · 2023Article
- Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal details of exoribonuclease activation and mRNA capping and provide starting points for antiviral drug development.Nucleic acids research · 2023Article
- Whole-Genome Comparison of Representatives of All Variants of SARS-CoV-2, Including Subvariant BA.2 and the GKA Clade.Advances in virology · 2023Article
- Challenges and developments in universal vaccine design against SARS-CoV-2 variants.NPJ vaccines · 2022Review
- PredictingACS omega · 2022Article
- Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview.Journal of diabetes and metabolic disorders · 2022Review
- Scaling Biosafety Up During and Down After the COVID-19 Pandemic.Applied biosafety : journal of the American Biological Safety Association · 2022Review
- The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness.Scientific reports · 2022Article
- An Electrostatically-steered Conformational Selection Mechanism Promotes SARS-CoV-2 Spike Protein Variation.Journal of molecular biology · 2022Article
Corrections and comments
- Erratum for
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.